top of page
HOME
About Us
News
Director's Message
Our Mission
PRINCIPLES
Bioregulartory PRINCIPLES
History
Pioneers
Philosophy
Basic Tenets
Environmental Factors
Epigenetics
Vaccines
COVID-19
DIAGNOSTICS
DIAGNOSTIC Philosophy
Etiology
Homotoxicology
Exams: H & P, Psychological
Disease Evolution Table
Darkfield Microscopy
THERAPEUTICS
THERAPEUTIC Modalities
Botanicals
Healing Found in Nature
Testimonials
RESOURCES
Articles
Books
e-Journals
Free Infographics
Educational Videos
PODCAST
BLOG
CONNECT
Subscribe | Contact
Submissions
Heidi Sullivan Award
Organizations
Health Freedom
Bioregulatory Equipment For Sale
EVENTS
Vitality and Beyond
Sign Up | Vitality and Beyond
BRMI 2024 Virtual Symposium
Calendar
Past Events
Homotoxicology Learning Modules
Sound Therapy Certification
DONATE
More
Use tab to navigate through the menu items.
LOW DOSE
NALTREXONE
BIOREGULATORY MEDICINE
Low Dose Naltrexone
All Categories
Play Video
Play Video
59:28
LDN Documentary
The LDN Story (A documentary about low dose naltrexone)
This documentary has been produced to promote wider knowledge of LDN (Low Dose Naltrexone). Hear from several practioners on how they use LDN with their patients and witness 2 remarkable stories on how LDN has changed the lives of a 8 year old Jacob Valazquez in Miami and Sarah Morton in the UK who was suffering from Fibromyalgia.
Play Video
Play Video
04:49
LDNscience
LDNscience® Presents - How LDN (Low Dose Naltrexone) Works
LDN is widely used for autoimmune disorders such as multiple sclerosis (MS), Crohn's disease, fibromyalgia, Hashimoto's thyroiditis, and other inflammatory and chronic disorders. View this scientific animation, produced by LDNscience, explaining how it works. LDNscience.org, launched in 2009, is a public information project of the MedInsight® Research Institute. Learn more at: https://ldnscience.org/
Play Video
Play Video
01:19:12
Ian Hewitt
Dr Bihari is Interviewed about Low Dose Naltrexone LDN for Normalizing Immune System Function
Interview with Bernard Bihari, MD: Low-dose Naltrexone for Normalizing Immune System Function Bernard Bihari, MD, (1931-2010) was the discoverer of the clinical effects of low-dose naltrexone (LDN) in humans. In his groundbreaking clinical trial of patients with HIV/AIDS at Downstate Medical Center in 1985-86, Dr Bihari discovered the significant effectiveness of low-dose naltrexone (LDN) in protecting the battered immune systems of those who were infected. With that knowledge, he entered private practice in an attempt to counter the then untreatable disease. As Dr Bihari explains below, the immune-system normalizing effect of the drug application he discovered applies to a wide range of autoimmune disorders. This interview was provided by Dr Bihari’s widow, from a videotape discovered after his death. The interview was transcribed and curated by Julia Schopick, author of Honest Medicine (www.honestmedicine.com) and champion of effective, cost-efficient treatments that are neglected by current practice. Content Courtesy of Alternative Therapies, Vol. 19, No 2 Since this interview, TNI BioTech has obtained the rights to the clinical data and the transfer of the Investigational New Drug (IND) and orphan drug designation for LDN from the US Food and Drug Administration for pancreatic cancer and Crohn’s disease. For more go to tnibiotech.com Bernard Bihari, MD, (1931-2010) was the discoverer of the clinical effects of low-dose naltrexone (LDN) in humans. In his groundbreaking clinical trial of patients with HIV/AIDS at Downstate Medical Center in 1985-86, Dr Bihari discovered the significant effectiveness of low-dose naltrexone in protecting the battered immune systems of those who were infected. With that knowledge, he entered private practice in an attempt to counter the then untreatable disease. As Dr Bihari explains below, the immune system normalizing effect of the drug application he discovered applies to a wide range of autoimmune disorders. This interview was provided by Dr Bihari’s widow, from a videotape discovered after his death. The interview was transcribed and curated by Julia Schopick, author of Honest Medicine (http://www.honestmedicine.com) and champion of effective, cost-efficient treatments that are neglected by current practice. (Altern Ther Health Med. 2013;19(2):56-65.) Since this interview, TNI BioTech has obtained the rights to the clinical data and the transfer of the Investigational New Drug (IND) and orphan drug designation for LDN from the US Food and Drug Administration for pancreatic cancer and Crohn’s disease. For more go to tnibiotech.com Since Dr. Bihari’s passing in 2010, a LDN Research Trust was set up by a group of multiple sclerosis patients to initiate clinical trials of LDN. The organization has assisted more than 14,000 patients to obtain LDN from a general practitioner or neurologist through the National Health Service in the UK or by prescription in other countries including the United States, Canada, Australia, New Zealand and the West Indies. The organization says they have helped patients with MS, Crohn’s, IBS. ME, some cancers and other immune-related diseases. For more go to ldnresearchtrust.org and YouTube.com/LDNScience.
bottom of page